Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause [Seeking Alpha]
Arvinas, Inc. (ARVN)
Last arvinas, inc. earnings: 11/4 05:00 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
Follow Play 8min Summary Arvinas, Inc.'s lead candidate, ARV-471, shows promise in phase 3 trials, especially in ESR1 mutant patients, but has mixed results in wild-type ESR1 patients. Despite past poor performance, recent positive data and a strong cash balance make ARVN a cautiously optimistic investment ahead of upcoming phase 3 data. Financially, Arvinas has a market cap of $1.78bn and a cash balance of $1.23bn, providing a runway of 8–9 quarters. While ARVN has potential, past inconsistent data warrants a cautious approach before investing further, despite promising recent developments. Hiroshi Watanabe I have been covering Arvinas, Inc. NASDAQ: ARVN ) for a long time, and I see that while I began with positive coverage back in 2021, my view has turned negative to neutral over the years. I also note that my negative articles have fared better than the positive ones in terms of the price movement since publication. That fact, validated over the last 4 years, tel
Show less
Read more
Impact Snapshot
Event Time:
ARVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARVN alerts
High impacting Arvinas, Inc. news events
Weekly update
A roundup of the hottest topics
ARVN
News
- Arvinas, Inc. (NASDAQ: ARVN) was given a new $26.00 price target on by analysts at Wells Fargo & Company. They now have an "overweight" rating on the stock.MarketBeat
- Arvinas, Inc. (NASDAQ: ARVN) was given a new $20.00 price target on by analysts at BMO Capital Markets.MarketBeat
- Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Bank of America Co. from $54.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
- Arvinas, Inc. (NASDAQ: ARVN) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. They now have a $12.00 price target on the stock, down previously from $57.00.MarketBeat
- Arvinas gets positive breast cancer data, but finds differentiation a hard sell [Yahoo! Finance]Yahoo! Finance
ARVN
Earnings
- 2/11/25 - Beat
ARVN
Sec Filings
- 3/11/25 - Form 8-K
- 2/25/25 - Form 4
- 2/25/25 - Form 4
- ARVN's page on the SEC website